Concepedia

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

Lars M. Wagner, Nancy McAllister, Robert E. Goldsby, Aaron R. Rausen, Rene McNall‐Knapp, M. Beth McCarville, Karen Albritton

Pediatric Blood & Cancer · 2005 · 196 citations · 27 references

DOI

Abstract

Temozolomide and protracted intravenous irinotecan given in 21-day courses was tolerable and active in patients with advanced ES. Home administration of irinotecan with temozolomide was safe and is reasonable palliative therapy. A formal Phase II study using a uniform dose and schedule is warranted to better define activity.

References

27

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone

Holcombe E. Grier, Mark Krailo, Nancy J. Tarbell et al. · New England Journal of Medicine · 2003 · 1.3K citations

Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group

Simon Cotterill, S. Ahrens, Michael Paulussen et al. · Journal of Clinical Oncology · 2000 · 1K citations

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

Peter J. Houghton, Pamela J. Cheshire, James D. Hallman et al. · Cancer Chemotherapy and Pharmacology · 1995 · 406 citations

, , +9

Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.

Kiyoshi Takasuna, Takehiro Hagiwara, Masaaki Hirohashi et al. · PubMed · 1996 · 338 citations

, , +14